[go: up one dir, main page]

CO2019013001A2 - Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer - Google Patents

Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer

Info

Publication number
CO2019013001A2
CO2019013001A2 CONC2019/0013001A CO2019013001A CO2019013001A2 CO 2019013001 A2 CO2019013001 A2 CO 2019013001A2 CO 2019013001 A CO2019013001 A CO 2019013001A CO 2019013001 A2 CO2019013001 A2 CO 2019013001A2
Authority
CO
Colombia
Prior art keywords
methods
grafted antibody
cancer treatment
antibody proteins
cytokine
Prior art date
Application number
CONC2019/0013001A
Other languages
English (en)
Inventor
Glen Spraggon
Yaiza Diaz-De-Durana
Michael Didonato
Christophe Filippi
Jonathan Deane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2019013001A2 publication Critical patent/CO2019013001A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C07K16/11—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención provee IL2 injertada en las secuencias CDR de un anticuerpo con terapéuticos preferidos por sobre las moléculas conocidas y utilizadas en la clínica. En particular, las composiciones de proteína de anticuerpo injertada con citocina provistas incrementan o mantienen las células efectoras CD8+ T mientras que reducen la actividad de las células Treg. Además, las composiciones provistas confieren una vida media, estabilidad y capacidad de producción mejorada por sobre las formulaciones de IL2 recombinante humana tales como Proleukin®.
CONC2019/0013001A 2017-05-24 2019-11-20 Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer CO2019013001A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762510533P 2017-05-24 2017-05-24
PCT/IB2018/053623 WO2018215936A1 (en) 2017-05-24 2018-05-22 Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CO2019013001A2 true CO2019013001A2 (es) 2020-01-17

Family

ID=62685011

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013001A CO2019013001A2 (es) 2017-05-24 2019-11-20 Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer

Country Status (16)

Country Link
US (2) US12006354B2 (es)
EP (1) EP3630813A1 (es)
JP (3) JP7791642B2 (es)
CN (1) CN110662762A (es)
AU (2) AU2018274216A1 (es)
BR (1) BR112019024556A2 (es)
CA (1) CA3063983A1 (es)
CL (1) CL2019003390A1 (es)
CO (1) CO2019013001A2 (es)
EA (1) EA201992765A1 (es)
IL (2) IL322309A (es)
MX (2) MX2019014023A (es)
MY (1) MY206158A (es)
PE (2) PE20251254A1 (es)
PH (1) PH12019502621A1 (es)
WO (1) WO2018215936A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
KR20200010354A (ko) 2017-05-24 2020-01-30 팬디온 테라퓨틱스, 인코포레이티드 표적화된 면역관용
AU2018274216A1 (en) * 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
JP6770274B1 (ja) * 2019-12-19 2020-10-14 株式会社ガク・アソシエイツ 境界線可視化システム、境界線可視化方法、境界線可視化プログラムおよびデジタルフォトアルバム作成システム
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
WO2021216920A1 (en) 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2021222762A2 (en) * 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Activatable il2 composition and methods of use
JP2023524108A (ja) 2020-05-04 2023-06-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US20230172987A1 (en) 2020-05-04 2023-06-08 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
CN116209676A (zh) 2020-06-22 2023-06-02 恩格姆生物制药公司 Lair-1结合剂及其使用方法
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230405129A1 (en) * 2020-10-20 2023-12-21 The Boad Of Regents Of The University Of Taxas System Proinflammatory prodrugs
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
EP4262811A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CA3202473A1 (en) 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Treatment of cancers with tumor infiltrating lymphocytes
WO2022147196A2 (en) 2020-12-31 2022-07-07 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
WO2022204155A1 (en) 2021-03-23 2022-09-29 Iovance Biotherapeutics, Inc. Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20220313806A1 (en) 2021-03-25 2022-10-06 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
TW202308669A (zh) 2021-04-19 2023-03-01 美商艾歐凡斯生物治療公司 嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
CA3219148A1 (en) 2021-05-17 2022-11-24 Frederick G. Vogt Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
US20240365776A1 (en) 2021-07-22 2024-11-07 Iovance Biotherapeutics, Inc Method for cryopreservation of solid tumor fragments
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
CA3243419A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. CYTOKINE-ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTE COMPOSITIONS AND PROCESSES
CA3247638A1 (en) 2022-04-06 2023-10-12 Maria Fardis TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
US20250281537A1 (en) 2022-05-10 2025-09-11 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
JP2025537155A (ja) 2022-11-04 2025-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
AU2024296516A1 (en) 2023-07-13 2026-01-22 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)

Family Cites Families (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA1291706C (en) 1986-04-03 1991-11-05 Alfred Rudolph COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
CA1290249C (en) 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0267615A3 (en) 1986-11-13 1989-05-03 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DE3856516T2 (de) 1987-09-22 2002-10-10 Chiron Corp., Emeryville Verwendung von rekombinantem koloniestimulierendem Faktor-1 zur Herstellung eines Medikaments gegen Cytomegalovirusinfektionen
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4999339A (en) 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en) 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5126129A (en) 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5229109A (en) * 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5306490A (en) 1992-04-20 1994-04-26 Medlogic, Inc. Methods for retarding blister formation by use of cyanoacrylate adhesives
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994004196A1 (en) 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU706443B2 (en) 1994-04-22 1999-06-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Melanoma antigens
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040176A1 (en) 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US6045788A (en) 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1997042217A1 (en) 1996-05-06 1997-11-13 The Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
AU758240B2 (en) 1998-02-25 2003-03-20 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US20030105294A1 (en) 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6013659A (en) 1998-09-04 2000-01-11 University Of Pittsburgh Methods of reducing tumor colony number using novel benzothiazole compounds
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PL200919B1 (pl) 1999-02-12 2009-02-27 Lexigen Pharm Corp Zastosowanie kompozycji czynnika hamującego angiogenezę i czynnika przeciwnowotworowego, kompozycja terapeutyczna do leczenia nowotworów i zestaw do traktowania komórki nowotworowej
US20020058609A1 (en) 1999-02-26 2002-05-16 Eli Gilboa Compositions and methods using complexes of calreticulin and antigenic molecules
WO2000059515A2 (en) 1999-04-02 2000-10-12 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
HU230271B1 (hu) 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
PL202058B1 (pl) 1999-08-09 2009-05-29 Merck Patent Gmbh Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU4050801A (en) 2000-01-20 2001-07-31 Unitectra Inc. Intra-tumoral administration of il-12 encoding nucleic acid molecules
AU2001253029A1 (en) 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
ATE414720T1 (de) 2000-12-05 2008-12-15 Alexion Pharma Inc Rationell entworfene antikörper
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
IL140796A0 (en) 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CN100522242C (zh) 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
WO2002097044A2 (en) 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
FR2825279B1 (fr) 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
JP2005507870A (ja) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア 低毒性のインターロイキン−２突然変異体
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
CN100390282C (zh) * 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
US20060084123A1 (en) 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
IL163851A0 (en) * 2002-03-01 2005-12-18 Immunomedics Inc Internalizing anti-cd74 antibodies and methods of use
BRPI0308113B8 (pt) 2002-03-08 2021-05-25 Eisai Co Ltd compostos macrocíclicos úteis como substâncias farmacêuticas
AU2003226141A1 (en) 2002-03-27 2003-10-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for treating cancer in humans
US7939641B2 (en) 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
NZ584663A (en) 2002-05-17 2011-09-30 Celgene Corp Use of immunomodulatory amino-dione derivatives for treating leukemia
MXPA04011310A (es) 2002-05-17 2005-02-14 Celgene Corp Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
EP2357005A1 (en) 2002-07-01 2011-08-17 Wilex AG Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ES2318167T3 (es) 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
CA2498284A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20040121971A1 (en) 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP1575615A1 (en) 2002-12-23 2005-09-21 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004080445A1 (en) 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
WO2004098529A2 (en) 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
US20060165744A1 (en) 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
WO2004108078A2 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP3943591A1 (en) 2003-10-08 2022-01-26 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
JP4912153B2 (ja) 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
ATE393169T1 (de) 2003-12-30 2008-05-15 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
CN1960728A (zh) 2004-01-16 2007-05-09 密歇根大学董事会 构象受限的smac模拟物及其应用
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005082368A1 (en) 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
JP5122275B2 (ja) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
BRPI0509721A (pt) 2004-04-07 2007-09-25 Novartis Ag inibidores de iap
NZ588799A (en) 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
MX2007000490A (es) 2004-07-12 2007-06-11 Idun Pharmaceuticals Inc Analogos de tetrapeptido.
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CN1721533A (zh) 2004-07-16 2006-01-18 中国科学院沈阳应用生态研究所 Il2与抗gd2单链抗体融合蛋白及编码基因和应用
EP1781338A4 (en) 2004-07-19 2010-02-10 Baylor College Medicine MODULATION OF CYTOKIN SIGNALING REGULATORS AND APPLICATIONS FOR IMMUNOTHERAPY
JP2008510829A (ja) 2004-08-25 2008-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン デンドリマーに基づく組成物およびそれらの使用法
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
US20060115485A1 (en) 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
ES2429541T3 (es) 2004-11-16 2013-11-15 Kalobios Pharmaceuticals, Inc. Intercambio de casete de región variable de inmunoglobulina
CU23297A1 (es) 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
ATE465176T1 (de) 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
DE602005022936D1 (de) 2004-12-20 2010-09-23 Genentech Inc Pyrrolidine als inhibitoren von iap
WO2006081510A2 (en) 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Methods for treating renal cell carcinoma
SI1688146T1 (sl) 2005-02-07 2007-12-31 Novartis Vaccines & Diagnostic Priprava aldesleukina za farmacevtsko uporabo
HRP20120709T1 (hr) 2005-02-18 2012-10-31 Medarex, Inc. Humano monoklonsko protutijelo za prostata-specifiäśni membranski antigen (psma)
CN101146549A (zh) 2005-02-18 2008-03-19 诺华疫苗和诊断公司 抗血管新生剂与阿地白介素
BRPI0607703A2 (pt) 2005-02-25 2009-09-22 Inotek Pharmaceutical S Corp compostos de isoquinolina e métodos de uso dos mesmos
EP1850848A4 (en) 2005-02-25 2008-02-20 Inotek Pharmaceuticals Corp SULFONAMIDE TETRACYCLIC COMPOUNDS AND METHODS OF USING THE SAME
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
NZ563245A (en) 2005-05-19 2011-04-29 Prometic Biosciences Inc Triazine compounds and compositions thereof for the treatment of cancers
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
PT1912636E (pt) 2005-07-21 2014-07-24 Ardea Biosciences Inc Inibidores de n-(arilamino)-sulfonamida de mek
WO2007030668A2 (en) 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
AU2006294819A1 (en) 2005-09-26 2007-04-05 Novacea, Inc. Prevention and treatment of gastrointestinal and bladder disorders using active vitamin D compounds
WO2007051119A1 (en) 2005-10-26 2007-05-03 Mgi Gp, Inc. Methods and compositions of parp inhibitors as potentiators in cancer therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007103009A2 (en) 2006-03-01 2007-09-13 Janssen Pharmaceutica N.V. CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
WO2008003473A2 (en) 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2008051220A1 (en) 2006-10-24 2008-05-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interaction of il-27 and il-2 for treatment of tumors
US20080221551A1 (en) 2007-03-09 2008-09-11 Flowmedica, Inc. Acute kidney injury treatment systems and methods
BRPI0808714A2 (pt) 2007-03-09 2014-08-12 Novartis Ag Uso de compostos, tais como 4-amino-5-fluoro-3-[6-(4-metil piperazinil-1)- 1h-benzimidazolil-2] quinolinona-(1h)-2 e tautômeros, sais, e misturas dos mesmos no preparo de medicamentos para o tratamento do melanoma
AU2008226337B2 (en) 2007-03-14 2012-02-16 BioLingus IP II GmbH Method for treating cancer via the mucosal administration of interleukin
AR066348A1 (es) 2007-04-30 2009-08-12 Genentech Inc Inhibidores de las iap
EP2150258A2 (en) 2007-06-01 2010-02-10 Innate Pharma S.A. Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
KR101584823B1 (ko) 2007-09-12 2016-01-22 제넨테크, 인크. 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
JP5439380B2 (ja) 2007-10-03 2014-03-12 エーザイ インク． Ｐａｒｐ阻害化合物、組成物及び使用方法
EP2050458A1 (en) 2007-10-17 2009-04-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL24 for inducing hyperproliferative or autoimmune cell death
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US20140127200A1 (en) 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
BRPI0821906B1 (pt) 2008-01-03 2022-06-07 The Scripps Research Institute Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira
ES2382058T3 (es) 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
JP5798919B2 (ja) 2008-08-25 2015-10-21 アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． Ｐｄ−１アンタゴニストの組成物および使用方法
WO2010042765A1 (en) 2008-10-08 2010-04-15 The Regents Of The University Of California Ca9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma
US20110268694A1 (en) 2009-01-12 2011-11-03 Robert Shalwitz Methods for treating vascular leak syndrome
CN102428105B (zh) 2009-02-24 2015-09-30 阿雷克森制药公司 含有治疗性tpo/epo模拟肽的抗体
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
US9005575B2 (en) 2009-06-12 2015-04-14 Stc.Unm Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
KR20120053042A (ko) 2009-08-17 2012-05-24 로슈 글리카트 아게 표적화된 면역접합체
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2011031865A1 (en) 2009-09-09 2011-03-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011066521A2 (en) 2009-11-30 2011-06-03 Stc. Unm Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
CN102762719A (zh) 2009-12-08 2012-10-31 威尔森沃尔夫制造公司 用于过继细胞疗法的细胞培养的改进方法
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
JP5786204B2 (ja) 2010-01-19 2015-09-30 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体
WO2011139738A2 (en) 2010-04-28 2011-11-10 Tenx Biopharma, Inc. Therapies using zanolimumab to enhance the immune response
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012021609A2 (en) 2010-08-12 2012-02-16 Ulrik Mouritzen Neoadjuvant treatment of cancer with proleukin
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US20120201750A1 (en) 2010-09-20 2012-08-09 Bungwoo Ryu Serum biomarkers for melanoma metastasis
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
BR112013019083A2 (pt) 2011-02-10 2017-04-04 Roche Glycart Ag combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
IL269687B (en) 2011-02-10 2022-08-01 Roche Glycart Ag Interleukin-2 polypeptides
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013044169A1 (en) 2011-09-21 2013-03-28 Nestec S.A. Methods for determining combination therapy with il-2 for the treatment of cancer
RU2628089C2 (ru) 2011-09-26 2017-08-14 Филоген С.П.А. Комбинированная терапия иммуноцитокинами
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
AU2012324644B2 (en) 2011-10-21 2014-08-28 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
AU2013208007A1 (en) 2012-01-09 2014-07-31 The Scripps Research Institute Humanized antibodies with ultralong CDR3
CN104520321A (zh) * 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
RU2633638C2 (ru) 2012-02-02 2017-10-16 Акселерон Фарма Инк. Антагонисты alk1 и их применение в лечении почечно-клеточной карциномы
CN104470535A (zh) 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
US9931359B2 (en) 2012-05-08 2018-04-03 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
IL307674A (en) 2012-05-18 2023-12-01 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
SG11201407819UA (en) 2012-06-11 2014-12-30 Wolf Wilson Mfg Corp Improved methods of cell culture for adoptive cell therapy
JP6290209B2 (ja) 2012-08-07 2018-03-07 ロシュ グリクアート アーゲー 低下した及び増加したエフェクター機能を有するように操作された２つの抗体を含む組成物。
CN104540848B (zh) 2012-08-08 2019-05-31 罗切格利卡特公司 白介素-10融合蛋白及其用途
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US9644021B2 (en) 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
CA2902423C (en) 2013-03-01 2021-06-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
CN111643524B (zh) 2013-03-01 2023-09-05 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
CN105358678A (zh) 2013-03-08 2016-02-24 密苏里大学董事会 治疗和/或预防1型糖尿病的方法和组合物
WO2014152122A2 (en) 2013-03-15 2014-09-25 Children's Medical Center Corporation Methods of altering vascular permeability and uses thereof
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
IL283236B1 (en) 2013-06-24 2025-10-01 Wilson Wolf Mfg Corporation Closed system device and methods for gas permeable cell culture process
CN112225817B (zh) 2013-07-11 2025-02-25 斯克利普斯研究所 卷曲螺旋免疫球蛋白融合蛋白及其组合物
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
EP3022221B1 (en) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
MX2016010174A (es) 2014-02-06 2016-11-15 Hoffmann La Roche Proteinas de fusion de interleucina-10 y usos de las mismas.
US11098099B2 (en) 2014-02-06 2021-08-24 Hoffmann-La Roche Inc. Interleukin-2 fusion proteins and uses thereof
DK3113793T3 (da) 2014-03-06 2021-01-18 Morphogenesis Inc Dna-vektor og transformerede tumorcellevacciner
EP3119419B1 (en) 2014-03-17 2019-04-03 Piotr Jachimczak Combination for use in a method of treating cancer
ES2906598T3 (es) 2014-03-17 2022-04-19 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch Inst Vertreten Durch Seinen Praeside Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular
CN106659913A (zh) 2014-03-20 2017-05-10 H.李莫菲特癌症中心研究院 用于过继细胞疗法的肿瘤浸润淋巴细胞
EP3154350B1 (en) 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
WO2015189357A1 (en) 2014-06-11 2015-12-17 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
RU2710354C2 (ru) 2014-08-29 2019-12-25 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе нацеленных на опухоль иммуноцитокинов, содержащих вариант il-2, и антител к человеческому pd-l1
CN119409799A (zh) 2014-10-02 2025-02-11 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
GB201419976D0 (en) 2014-11-10 2014-12-24 Univ Newcastle Biomarkers for disease progression in melanoma
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
WO2017093947A1 (en) 2015-12-04 2017-06-08 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
SG11201805493YA (en) 2016-01-08 2018-07-30 Iontas Ltd Binding members with altered diversity scaffold domains
SI3532607T1 (sl) 2016-10-26 2024-06-28 Iovance Biotherapeutics, Inc. Restimulacija limfocitov, ki infiltrirajo kriokonzervirani tumor
AU2018274216A1 (en) * 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer

Also Published As

Publication number Publication date
CL2019003390A1 (es) 2020-03-13
EP3630813A1 (en) 2020-04-08
JP7774025B2 (ja) 2025-11-20
US12006354B2 (en) 2024-06-11
PE20251254A1 (es) 2025-05-06
EA201992765A1 (ru) 2020-03-25
JP2024023225A (ja) 2024-02-21
PE20200303A1 (es) 2020-02-06
MX2024012897A (es) 2024-11-08
JP7791642B2 (ja) 2025-12-24
PH12019502621A1 (en) 2020-06-08
AU2021250843A1 (en) 2021-11-04
US20200270334A1 (en) 2020-08-27
CA3063983A1 (en) 2018-11-29
AU2018274216A1 (en) 2019-12-12
KR20200010468A (ko) 2020-01-30
WO2018215936A1 (en) 2018-11-29
US20240141022A1 (en) 2024-05-02
RU2019142479A (ru) 2021-06-25
JP2020520665A (ja) 2020-07-16
JP2025060802A (ja) 2025-04-10
MX2019014023A (es) 2020-02-17
AU2021250843B2 (en) 2025-02-27
BR112019024556A2 (pt) 2020-06-23
CN110662762A (zh) 2020-01-07
IL270814A (en) 2020-01-30
MY206158A (en) 2024-12-02
RU2019142479A3 (es) 2021-10-01
IL322309A (en) 2025-09-01

Similar Documents

Publication Publication Date Title
CO2019013001A2 (es) Proteínas de anticuerpo injertadas con citocina y métodos de uso en el tratamiento del cáncer
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
MX389568B (es) Péptidos y uso de los mismos en inmunoterapia contra varios tumores, tales como cáncer de pulmón, que incluye cáncer de pulmón de células no pequeñas (nsclc)
MX392416B (es) Métodos y composiciones para terapia celular adoptiva.
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
MX379423B (es) Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
MX2020011674A (es) Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
EA201300322A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
BR112014014678A2 (pt) composições oftálmicas compreendendo copolímeros de enxertia de polivinil caprolactama-acetato de polivinila-polietileno glicol
WO2018081726A3 (en) Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
EA201690680A1 (ru) Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма
BR112021024822A2 (pt) Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.